Back

The effects of SGLT2 inhibitors in patients with preserved ejection fraction heart failure and type 2 diabetes: A randomized case-control study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Echocardiography to predict outcome across different diseases Tissue Doppler, Speckle Tracking and Strain Imaging ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Islam Shehata

Zagazig University, Zagazig (Egypt)

7 More presentations in this session

Presentation thumbnail
Evaluation of implementation of artificial intelligence (AI)-assisted echocardiography in clinical practice
Doctor L. Wright (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Long-term prognostic value of myocardial work analysis across obesity stages: insights from a community-based study
Doctor F. Zhubi Bakija (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Cardiac remodeling and Left Ventricular Global Longitudinal Strain (LV-GLS) in CKD: do advanced stages impair myocardial function?
Doctor H. Villarraga (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Long-term risk of major adverse cardiovascular events in individuals with type 1 diabetes, albuminuria, and cardiac impairment
Doctor E. Frimodt-Moeller (Herlev, DK)
Abstract Slides Video
Presentation thumbnail
Functional and prognostic value of mitral regurgitation assessment during exercise stress echocardiography
Associate Professor Q. Ciampi (Benevento, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Echocardiography to predict outcome across different diseases

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Short-term effects of SGLT2 inhibitors on myocardial extracellular volume, left ventricular function and inflammation in patients with HFpEF and diabetes mellitus
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Presentation
Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources